Loading
A phase 3 trial testing Domvanalimab in non-small-cell lung cancer, active and no longer recruiting.
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC is a phase 3 interventional study registered as NCT05211895, led by AstraZeneca with Arcus Biosciences, and active but no longer recruiting on the registry. Official title: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy. Planned enrolment is 791 participants (actual). The study started in 2022-02-18 and primary completion is expected in 2026-08-10. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Domvanalimab, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Domvanalimab, Non-small-cell lung cancer.
Shares Domvanalimab, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/